O	0	8	Survival
O	9	17	outcomes
O	18	20	of
B-intervention	21	32	neoadjuvant
I-intervention	33	45	chemotherapy
I-intervention	46	50	with
I-intervention	51	61	zoledronic
I-intervention	62	66	acid
O	67	70	for
O	71	75	HER2
O	75	76	-
O	76	84	negative
O	85	91	breast
O	92	98	cancer
O	98	99	.

O	100	101	A
O	102	112	randomized
O	113	118	phase
O	119	120	2
O	121	126	trial
O	127	129	in
O	130	135	women
O	136	140	with
O	141	145	HER2
O	145	146	-
O	146	154	negative
O	155	161	breast
O	162	168	cancer
O	169	172	has
O	173	178	shown
O	179	183	that
O	184	190	adding
O	191	201	zoledronic
O	202	206	acid
O	207	208	(
O	208	211	ZOL
O	211	212	)
O	213	215	to
O	216	227	neoadjuvant
O	228	240	chemotherapy
O	241	242	(
O	242	244	CT
O	244	245	)
O	246	249	has
O	250	259	potential
O	260	270	anticancer
O	271	279	benefits
O	280	282	in
O	283	297	postmenopausal
O	298	301	and
O	302	308	triple
O	308	309	-
O	309	317	negative
O	318	319	(
O	319	321	TN
O	321	322	)
O	323	329	breast
O	330	336	cancer
O	337	345	patients
O	345	346	.

O	347	349	We
O	350	356	report
O	357	360	the
O	361	365	data
O	366	369	for
O	370	373	the
O	374	383	secondary
O	384	387	end
O	388	393	point
O	394	396	of
O	397	404	disease
O	404	405	-
O	405	409	free
O	410	418	survival
O	419	420	(
O	420	423	DFS
O	423	424	)
O	424	425	.

O	426	434	Patients
O	435	439	were
O	440	448	randomly
O	449	457	assigned
O	458	460	to
O	461	468	receive
O	469	471	CT
O	472	474	or
O	475	477	CT
O	478	479	+
O	480	483	ZOL
O	484	485	(
O	485	487	CT
O	487	488	-
O	488	489	Z
O	489	490	)
O	490	491	.

O	492	495	All
O	496	504	patients
O	505	513	received
O	514	518	four
O	519	525	cycles
O	526	528	of
O	529	535	FEC100
O	536	544	followed
O	545	547	by
O	548	550	12
O	551	557	cycles
O	558	560	of
O	561	571	paclitaxel
O	572	578	weekly
O	578	579	.

O	580	583	ZOL
O	584	585	(
O	585	586	4
O	587	589	mg
O	589	590	)
O	591	594	was
O	595	607	administered
O	608	609	3
O	609	610	-
O	610	611	4
O	612	617	times
O	618	624	weekly
O	625	628	for
O	629	630	7
O	631	633	wk
O	634	636	to
O	637	640	the
O	641	643	CT
O	643	644	-
O	644	645	Z
O	646	651	group
O	652	660	patients
O	660	661	.

O	662	665	The
O	666	673	primary
O	674	677	end
O	678	683	point
O	684	687	was
B-outcome-Measure	688	698	pathologic
I-outcome-Measure	699	707	complete
I-outcome-Measure	708	716	response
I-outcome-Measure	717	718	(
I-outcome-Measure	718	721	pCR
I-outcome-Measure	721	722	)
O	722	723	.

O	724	727	The
O	728	737	secondary
O	738	741	end
O	742	748	points
O	749	753	were
O	754	757	the
B-outcome-Measure	758	766	clinical
I-outcome-Measure	767	775	response
I-outcome-Measure	776	781	rates
O	781	782	,
B-outcome-Measure	783	787	rate
I-outcome-Measure	788	790	of
I-outcome-Measure	791	797	breast
I-outcome-Measure	797	798	-
I-outcome-Measure	798	808	conserving
I-outcome-Measure	809	816	surgery
O	816	817	,
B-outcome-Measure	818	824	safety
O	824	825	,
O	826	829	and
B-outcome-Measure	830	833	DFS
O	833	834	.

O	835	837	Of
O	838	841	the
B-total-participants	842	845	188
O	846	854	patients
O	855	863	enrolled
O	863	864	,
B-control-participants	865	867	95
O	868	872	were
O	873	881	assigned
O	882	884	to
O	885	888	the
O	889	891	CT
O	892	897	group
O	898	901	and
B-intervention-participants	902	904	93
O	905	907	to
O	908	911	the
O	912	914	CT
O	914	915	-
O	915	916	Z
O	917	922	group
O	922	923	.

B-outcome	924	927	DFS
O	928	931	and
B-outcome	932	939	overall
I-outcome	940	948	survival
O	949	953	were
O	954	962	analyzed
O	963	965	in
B-control-participants	966	968	92
O	969	972	and
B-intervention-participants	973	975	88
O	976	984	patients
O	985	989	with
O	990	993	the
O	994	998	mean
O	999	1004	times
O	1005	1007	of
B-cv-cont-mean	1008	1009	5
I-cv-cont-mean	1009	1010	.
I-cv-cont-mean	1010	1012	15
I-cv-cont-mean	1013	1014	y
O	1015	1018	and
B-iv-cont-mean	1019	1020	5
I-iv-cont-mean	1020	1021	.
I-iv-cont-mean	1021	1023	38
I-iv-cont-mean	1024	1025	y
O	1025	1026	,
O	1027	1039	respectively
O	1039	1040	.

O	1041	1044	The
B-outcome	1045	1046	3
I-outcome	1046	1047	-
I-outcome	1047	1048	y
I-outcome	1049	1052	DFS
I-outcome	1053	1057	rate
O	1058	1061	was
B-cv-bin-percent	1062	1064	84
I-cv-bin-percent	1064	1065	.
I-cv-bin-percent	1065	1066	6
I-cv-bin-percent	1066	1067	%
O	1068	1070	in
O	1071	1074	the
O	1075	1077	CT
O	1078	1083	group
O	1084	1087	and
B-iv-bin-percent	1088	1090	90
I-iv-bin-percent	1090	1091	.
I-iv-bin-percent	1091	1092	8
I-iv-bin-percent	1092	1093	%
O	1094	1096	in
O	1097	1100	the
O	1101	1103	CT
O	1103	1104	-
O	1104	1105	Z
O	1106	1111	group
O	1112	1113	(
O	1113	1114	P
O	1115	1116	=
O	1117	1118	0
O	1118	1119	.
O	1119	1122	188
O	1122	1123	)
O	1123	1124	.

O	1125	1128	The
O	1129	1139	particular
O	1140	1147	benefit
O	1148	1152	from
O	1153	1156	ZOL
O	1157	1160	for
O	1161	1164	the
O	1165	1176	neoadjuvant
O	1177	1179	CT
O	1180	1184	seen
O	1185	1187	as
O	1188	1199	improvement
O	1200	1202	of
O	1203	1206	the
B-outcome	1207	1210	pCR
I-outcome	1211	1215	rate
O	1216	1219	was
O	1220	1229	indicated
O	1230	1232	in
O	1233	1236	the
O	1237	1238	3
O	1238	1239	-
O	1239	1240	y
O	1241	1244	DFS
O	1245	1251	period
O	1252	1255	for
O	1256	1258	TN
O	1259	1265	cancer
O	1266	1271	cases
O	1272	1273	(
O	1273	1275	CT
O	1276	1282	versus
O	1283	1285	CT
O	1285	1286	-
O	1286	1287	Z
O	1287	1288	:
B-cv-bin-percent	1289	1291	70
I-cv-bin-percent	1291	1292	.
I-cv-bin-percent	1292	1293	6
I-cv-bin-percent	1293	1294	%
O	1295	1301	versus
B-iv-bin-percent	1302	1304	94
I-iv-bin-percent	1304	1305	.
I-iv-bin-percent	1305	1306	1
I-iv-bin-percent	1306	1307	%
O	1307	1308	)
O	1309	1312	but
O	1313	1316	not
O	1317	1320	for
O	1321	1335	postmenopausal
O	1336	1341	cases
O	1341	1342	.

O	1343	1346	ZOL
O	1347	1350	did
O	1351	1354	not
O	1355	1362	improve
B-outcome	1363	1366	DFS
O	1367	1371	when
O	1372	1380	combined
O	1381	1385	with
O	1386	1388	CT
O	1388	1389	.

O	1390	1397	However
O	1397	1398	,
O	1399	1402	the
O	1403	1414	improvement
O	1415	1417	of
O	1418	1421	the
O	1422	1425	pCR
O	1426	1430	rate
O	1431	1441	translated
O	1442	1444	to
O	1445	1453	survival
O	1454	1462	outcomes
O	1463	1465	in
O	1466	1468	TN
O	1469	1475	breast
O	1476	1482	cancer
O	1482	1483	.

O	1484	1487	The
O	1488	1493	short
O	1493	1494	-
O	1494	1498	term
O	1499	1510	application
O	1511	1513	of
O	1514	1517	ZOL
O	1518	1521	may
O	1522	1525	not
O	1526	1528	be
O	1529	1539	sufficient
O	1540	1542	to
O	1543	1550	improve
O	1551	1554	the
O	1555	1562	outcome
O	1563	1565	in
O	1566	1580	postmenopausal
O	1581	1589	patients
O	1589	1590	.
